US industry lobbies HHS on in vitro diagnostics
This article was originally published in Clinica
Executive Summary
The US FDA's limited resources should be focused on novel technology with the highest risk, the industry association, AdvaMed, told a Health and Human Services (HHS) department committee meeting on February 13.